An observational study in Primary Biliary Cholangitis (PBC), sponsored by Humanity and Health Research Centre. Completed at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-03-24.
Sponsored by Humanity and Health Research Centre · Observational
Several risk assessment scoring systems have been proposed to assess the therapeutic response and predict long term prognosis in ursodeoxycholic acid (UDCA)-treated primary biliary cholangitis (PBC) patients, in order to risk stratify PBC patients and guide their management. However there scoring systems have not been fully validated in Chinese population. This study is going to compare the prognostic ability of these criteria, validate the overseas scoring systems, develop and validate a new scoring system in a cohort of Chinese PBC patients.
Patients with PBC who are referred to centre of non-infectious liver diseases, Beijing 302 Hospital, Beijing from 2010 will be evaluated.
Exclusion Criteria:
Ursodeoxycholic acid will be given compliance to the treatment guideline.
Drug: Ursodeoxycholic Acid
Standard care of PBC patients
Liver related Death
Whether the patients die from liver-related causes during the follow-up
Time frame: During follow-up after a year of starting UDCA, an average of 1 year
Complications of cirrhosis
Whether the complication of cirrhosis i.e. ascites, hepatic encephalopathy, variceal bleeding occur during the follow-up
Time frame: During follow-up after a year of starting UDCA, an average of 1 year
Liver transplant
Whether the patients have liver transplant during the follow-up
Time frame: During follow-up after a year of starting UDCA, an average of 1 year
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Humanity and Health Research Centre